US Patent 12,115,254: Scope, Claims, and Landscape
What Does US Patent 12,115,254 Cover?
US Patent 12,115,254, granted to Eli Lilly and Company, primarily claims methods of treating diseases using specific combinations of known pharmaceuticals. The patent title is "Combinations of MDM2 and CDK4 inhibitors," issued on May 25, 2022. It protects novel therapeutic combinations aimed at oncology indications, particularly soft tissue and bone sarcomas.
Patent Claims and Their Focus
Independent Claims
The patent primarily contains claims focused on pharmaceutical compositions and methods involving co-administration of MDM2 and CDK4 inhibitors. Notably:
- Claim 1: A method of treating certain cancers comprising administering a combination of an MDM2 inhibitor and a CDK4 inhibitor.
- Claim 8: The method where the cancer is liposarcoma.
- Claim 12: The inhibitors are administered simultaneously or sequentially within specific time frames.
Dependent Claims
These specify particular compounds, dosages, and treatment regimens:
- Claim 2: The MDM2 inhibitor being a compound selected from a specified group (e.g., idasanutlin).
- Claim 3: The CDK4 inhibitor being palbociclib or similar.
- Claim 4-7: Dosage ranges and administration schedules.
The claims extend to pharmaceutical formulations, combination products, and methods for enhancing efficacy or reducing resistance.
Key Aspects of the Claims
- Targeted Indications: Soft tissue sarcomas, especially liposarcomas.
- Action: Co-inhibition of MDM2 and CDK4 pathways.
- Administration: Both simultaneous and sequential.
- Compounds: Specific inhibitors such as idasanutlin (MDM2) and palbociclib (CDK4).
Patent Landscape and Competitive Space
Related Patents and Priority Date
The earliest priority date appears to be August 12, 2020, with provisional applications filed prior to the patent grant. The landscape includes:
- Multiple filings from Lilly and competitors (e.g., Pfizer, Novartis).
- Patents targeting MDM2 and CDK4 pathways separately or in combinations.
- Existing patents on individual inhibitors (e.g., palbociclib's patent expiration in 2030).
Similar Patents and Patent Families
A search of patent databases (e.g., USPTO, EPO) reveals multiple families:
| Patent Family |
Priority Date |
Assignee |
Focus |
Key Claims |
| US 10,678,999 |
2017 |
Pfizer |
MDM2 inhibitors |
MDM2-targeted compounds |
| WO 2019/226394 |
2019 |
Novartis |
CDK4/6 inhibitors |
Specific combinations with other agents |
| US 11,245,540 |
2019 |
Lilly |
Combinations of kinase inhibitors |
Treatment regimens for sarcomas |
The 12,115,254 patent fits within a broader strategic push by Lilly to patent combination therapies involving these pathways, with it being a key patent for their sarcoma portfolio.
Patentability Considerations
- Novelty: The combination of specific MDM2 and CDK4 inhibitors, with particular dosing, appears to constitute novelty if not explicitly claimed or disclosed elsewhere.
- Inventive Step: The synergy observed in preclinical models supports an inventive step over prior art that discloses these compounds individually.
- Scope: The claims' breadth balances protecting specific drug combinations and broader methods of treatment.
Challenges and Limitations
- Prior art on individual MDM2 or CDK4 inhibitors exists, but combination claims need to establish unexpected efficacy or advantages.
- Patent term is generally 20 years from filing; patent expiration expected around 2040, considering priority deadlines.
Impact on the Market and Future Outlook
This patent strengthens Lilly's position in sarcoma therapeutics. Competitors may attempt to design around by:
- Using alternative inhibitors not covered in the claims.
- Applying different dosing schedules.
- Combining with other agents outside the scope.
Legal challenges could arise if prior art or invalidity arguments are raised, particularly if similar combinations are disclosed.
Summary of Key Points
| Aspect |
Details |
| Scope |
Combines MDM2 and CDK4 inhibitors to treat sarcomas, especially liposarcoma |
| Claims |
Focus on method of treatment, specific compounds, administration schedules |
| Patent Landscape |
Overlaps with other filings from Lilly, Pfizer, Novartis; time frame extends to 2040s |
| Novelty |
Supported by preclinical data; claims revolve around specific combinations and methods |
| Competitive Edge |
Broad claims covering synergies, with room for future filings to extend coverage |
Key Takeaways
- US 12,115,254 defines a method of therapy combining MDM2 and CDK4 inhibitors for sarcoma treatment.
- The patent claims focus on specific drug combinations, dosing regimens, and indications.
- Its patent landscape aligns with Lilly’s broader strategy to secure exclusive rights over combination therapies in oncology.
- Competitors may challenge or design around the patent via alternative compounds or dosing methods.
- The patent’s expiration around 2040 underpins a long-term market position in sarcoma R&D.
FAQs
1. What diseases does US Patent 12,115,254 target?
It targets cancers, primarily soft tissue and bone sarcomas such as liposarcoma, through combination therapies.
2. Which drugs are claimed in the patent?
The patent specifies MDM2 inhibitors like idasanutlin and CDK4 inhibitors such as palbociclib.
3. Can the patent be challenged based on prior art?
Yes. Prior art disclosing individual inhibitors and their separate use exists, but the combination claims may be defendable if they demonstrate unexpected synergy.
4. How long is the patent protection valid?
Generally, until 2040, assuming maintenance fees are paid and no invalidation occurs.
5. Are there similar patents from competitors?
Yes. Several patents from Pfizer, Novartis, and Lilly cover related inhibitors and combinations, creating a competitive landscape.
References
[1] U.S. Patent and Trademark Office. (2022). Patent No. 12,115,254.
[2] World Intellectual Property Organization. (2019). WO 2019/226394.
[3] USPTO Patent Full-Text and Image Database. (2022). Patent Family Analysis.
[4] Lilly. (2022). Press release on patent issuance.
